Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

Abstract Background About 50% of older patients with acute myeloid leukemia (AML) fail to attain complete remission (CR) following cytarabine plus anthracycline-based induction therapy. Salvage chemotherapy regimens are based on high-dose cytarabine (HiDAC), which is frequently combined with mitoxan...

Full description

Bibliographic Details
Main Authors: Sonia Jaramillo, Lucian Le Cornet, Markus Kratzmann, Johannes Krisam, Martin Görner, Mathias Hänel, Christoph Röllig, Maxi Wass, Sebastian Scholl, Mark Ringhoffer, Alexander Reichart, Björn Steffen, Sabine Kayser, Jan-Henrik Mikesch, Kerstin Schaefer-Eckart, Jörg Schubert, Thomas Geer, Sonja Martin, Meinhard Kieser, Tim Sauer, Katharina Kriegsmann, Michael Hundemer, Hubert Serve, Martin Bornhäuser, Carsten Müller-Tidow, Richard F. Schlenk
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Trials
Subjects:
Quizartinib
Relapse
Refractory
Acute myeloid leukemia
Measurable residual disease
Matched threshold crossing approach
Online Access:https://doi.org/10.1186/s13063-023-07421-x

Internet

https://doi.org/10.1186/s13063-023-07421-x

Similar Items